Rexista is different. I don't believe that FDA will reject. IMHO Rexista is not greatly different than others on the market. I would liken it to being somewhat like another "generic" ADF version. What will make it different is PODRAS IMO.
I am long because of what I think the growth and takeover prospects are for this company. My risk to reward IMO is favorable. And if IPCI proves out PODRAS, the reward should be significant. Honestly I believe some of what is holding IPCI back is they are not currently actively developing anything in the pipeline. ANDAs are just waiting. Rexista testing is most likely done. Rexista PODRAS is sitting. Regabatin is sitting. Nothing is presently in development mode.
I did not say Rexista is nothing useful. According to IPCI they are the first to claim equivalency to Oxycontin. So it works the same. For the majority of people that do NOT abuse the product it would be no different than taking Oxycontin excepting the food effect. But I think there is opportunity to BUILD ON Rexista .... i.e. the platform. The 24 hr XR.
News 
Market Data 
Discover 
AI
